| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 293 | 2018 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 243 | 2019 |
| Characterization of familial Waldenström's macroglobulinemia SP Treon, ZR Hunter, A Aggarwal, EP Ewen, S Masota, C Lee, DD Santos, ... Annals of Oncology 17 (3), 488-494, 2006 | 222 | 2006 |
| Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling JM Chan, S Zaidi, JR Love, JL Zhao, M Setty, KM Wadosky, A Gopalan, ... Science 377 (6611), 1180-1191, 2022 | 111 | 2022 |
| Venous thromboembolism: diagnosis and management of deep venous thrombosis WK Ho, GJ Hankey, CH Lee, JW Eikelboom Medical journal of Australia 182 (9), 476-481, 2005 | 109 | 2005 |
| Weighted frequent gene co-expression network mining to identify genes involved in genome stability J Zhang, K Lu, Y Xiang, M Islam, S Kotian, Z Kais, C Lee, M Arora, H Liu, ... Public Library of Science 8 (8), e1002656, 2012 | 90 | 2012 |
| Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time SK Kumar, A Dispenzieri, R Fraser, F Mingwei, G Akpek, R Cornell, ... Leukemia 32 (4), 986-995, 2018 | 73 | 2018 |
| Venous thromboembolism: diagnosis and management of pulmonary embolism CH Lee, GJ Hankey, WK Ho, JW Eikelboom Medical journal of Australia 182 (11), 569-574, 2005 | 55 | 2005 |
| Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis A Mahindra, P Hari, R Fraser, M Fei, J Huang, J Berdeja, N Callander, ... Bone marrow transplantation 52 (12), 1616-1622, 2017 | 52 | 2017 |
| Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, ... Internal Medicine Journal 50 (6), 667-679, 2020 | 46 | 2020 |
| Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma H Quach, S Benson, H Haysom, AM Wilkes, N Zacher, M Cole‐Sinclair, ... Internal Medicine Journal 48 (2), 210-220, 2018 | 45 | 2018 |
| Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation GL Uy, LJ Costa, PN Hari, MJ Zhang, JX Huang, KC Anderson, ... Bone marrow transplantation 50 (12), 1513-1518, 2015 | 41 | 2015 |
| DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple … R Popat, A Nooka, K Stockerl-Goldstein, R Abonour, R Ramaekers, ... Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020 | 40 | 2020 |
| Post-transplant outcomes in high-risk compared with non–high-risk multiple myeloma: a CIBMTR analysis EC Scott, P Hari, M Sharma, J Le-Rademacher, J Huang, D Vogl, M Abidi, ... Biology of Blood and Marrow Transplantation 22 (10), 1893-1899, 2016 | 40 | 2016 |
| Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk K Weisel, A Spencer, S Lentzsch, H Avet-Loiseau, TM Mark, I Spicka, ... Journal of hematology & oncology 13, 1-11, 2020 | 39 | 2020 |
| Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival M Htut, A D'Souza, A Krishnan, B Bruno, MJ Zhang, M Fei, MA Diaz, ... Biology of Blood and Marrow Transplantation 24 (3), 478-485, 2018 | 37 | 2018 |
| Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia ELJ Smits, C Lee, N Hardwick, S Brooks, VFI Van Tendeloo, K Orchard, ... Cancer Immunology, Immunotherapy 60, 757-769, 2011 | 37 | 2011 |
| Functional analysis of BARD1 missense variants in homology‐directed repair of DNA double strand breaks C Lee, T Banerjee, J Gillespie, A Ceravolo, MR Parvinsmith, LM Starita, ... Human mutation 36 (12), 1205-1214, 2015 | 34 | 2015 |
| Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity AI Adamovich, T Banerjee, M Wingo, K Duncan, J Ning, ... PLoS genetics 15 (3), e1008049, 2019 | 33 | 2019 |
| Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era B Dhakal, S Patel, S Girnius, L Bachegowda, R Fraser, O Davila, ... Leukemia 34 (12), 3338-3347, 2020 | 32 | 2020 |
